An interesting ongoing phase I clinical trial is combining navitoclax, an early BH3 mimetic targeting not only BCL2 but also MCL1 and BCL-Xl, with AZA/VEN (NCT05222984) to treat AML patients previously treated with VEN-based therapy. This evidence concerns the gene BCL2L1 and acute myeloid leukemia.